-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News April 21 Bispecific Antibodies (Bispecific Antibodies, BsAb) refers to antibodies that can bind two different antigens or different epitopes of an antigen at the same time, and can use its unique mode of action, such as connecting T cells and tumor cells , Synergistically inhibit signal pathways, form protein complexes, etc.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
Monoclonal antibody drugs generally use IgG type antibodies, including two Fab regions and an Fc region; dual-antibody drugs are structurally divided into full-length dual antibodies (similar in structure to IgG monoclonal antibodies, with Fc region) and fragment dual antibodies (made from IgG The Fab region of the monoclonal antibody is composed of two types, without the Fc region.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
The presence or absence of the Fc region has two sides to the effect of double-antibody drugs.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
Bispecific antibodies have three mechanisms of action, which can target multiple antigens or epitopes, and their synergistic effects are more advantageous than monoclonal antibodies, and they can also mediate a variety of specific biological effects: one is bridge Combine immune cells and tumor cells, and kill tumor cells by recruiting and activating immune cells, including T cell bridging and NK cell bridging.
Catumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
Catumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
As of October 2020, 3 dual-antibody drugs have been approved for marketing worldwide, with indications including tumors and hemophilia.
In 2018, 27 of the 28 newly initiated clinical trials of dual-antibody drugs were on the tumor direction.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
At present, the global research and development of dual-antibody drugs is mainly concentrated in phase I and phase II clinical studies, and a small number of drugs are in phase III clinical studies.
The dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
The dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
Technology platform development and commercialization of three bispecific antibodies.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
Dual antibody drugs have shown better efficacy than monoclonal antibody combination therapy, CAR-T and small molecule drugs, and effective responses have even appeared in patients whose existing therapies have failed or developed drug resistance.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
Medical Network News April 21 Bispecific Antibodies (Bispecific Antibodies, BsAb) refers to antibodies that can bind two different antigens or different epitopes of an antigen at the same time, and can use its unique mode of action, such as connecting T cells and tumor cells , Synergistically inhibit signal pathways, form protein complexes, etc.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
Monoclonal antibody drugs generally use IgG type antibodies, including two Fab regions and an Fc region; dual-antibody drugs are structurally divided into full-length dual antibodies (similar in structure to IgG monoclonal antibodies, with Fc region) and fragment dual antibodies (made from IgG The Fab region of the monoclonal antibody is composed of two types, without the Fc region.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
The presence or absence of the Fc region has two sides to the effect of double-antibody drugs.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
Bispecific antibodies have three mechanisms of action, which can target multiple antigens or epitopes, and their synergistic effects are more advantageous than monoclonal antibodies, and they can also mediate a variety of specific biological effects: one is bridge Combine immune cells and tumor cells, and kill tumor cells by recruiting and activating immune cells, including T cell bridging and NK cell bridging.
Catumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
Catumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
As of October 2020, 3 dual-antibody drugs have been approved for marketing worldwide, with indications including tumors and hemophilia.
In 2018, 27 of the 28 newly initiated clinical trials of dual-antibody drugs were on the tumor direction.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
At present, the global research and development of dual-antibody drugs is mainly concentrated in phase I and phase II clinical studies, and a small number of drugs are in phase III clinical studies.
The dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
The dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
Technology platform development and commercialization of three bispecific antibodies.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
Dual antibody drugs have shown better efficacy than monoclonal antibody combination therapy, CAR-T and small molecule drugs, and effective responses have even appeared in patients whose existing therapies have failed or developed drug resistance.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
Medical Network News April 21 Bispecific Antibodies (Bispecific Antibodies, BsAb) refers to antibodies that can bind two different antigens or different epitopes of an antigen at the same time, and can use its unique mode of action, such as connecting T cells and tumor cells , Synergistically inhibit signal pathways, form protein complexes, etc.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
, exerting biological functions that monoclonal antibodies cannot achieve.
To put it simply, double-antibody drugs are formed by fusing two different monoclonal antibody structures, but they involve the unique technical difficulty of double-strand mismatch.
Monoclonal antibody drugs generally use IgG type antibodies, including two Fab regions and an Fc region; dual-antibody drugs are structurally divided into full-length dual antibodies (similar in structure to IgG monoclonal antibodies, with Fc region) and fragment dual antibodies (made from IgG The Fab region of the monoclonal antibody is composed of two types, without the Fc region.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
Whether there are tissue permeability, immunogenicity, half-life, stability and other problems caused by the molecular structure of the Fc fragment, as well as various problems such as functionality, affinity, titer (the amount of antigen binding), and antigenic characteristics, make double-antibody drugs The threshold for research and development is very high, and the required balance of safety, effectiveness, and druggability is much higher than that of monoclonal antibody drugs.
The presence or absence of the Fc region has two sides to the effect of double-antibody drugs.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
In actual research and development, it is necessary to select the size of the antibody molecule in combination with clinical indications, and consider whether to retain the Fc region.
The construction of the dual antibody technology platform is therefore different.
Typical fragment dual-antibody technology platforms include Amgen's BiTE platform, Sanofi's Nanobody platform, etc.
; typical full-length dual-antibody technology platforms include Roche's KiH platform, CrossMab platform, ART-lg platform, and AbbVie's DVD- lg platform, etc.
Bispecific antibodies have three mechanisms of action, which can target multiple antigens or epitopes, and their synergistic effects are more advantageous than monoclonal antibodies, and they can also mediate a variety of specific biological effects: one is bridge Combine immune cells and tumor cells, and kill tumor cells by recruiting and activating immune cells, including T cell bridging and NK cell bridging.
Catumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
Disease disease diseaseCatumaxomab approved by the European Union in 2009 and Blinatumomab approved by the US FDA in 2014 both applied this mechanism of action.
The second is to inhibit or stimulate multiple signal pathways to play a coordination effect.
The occurrence of tumors and other diseases often involves multiple signal pathways.
Blocking a single signal pathway often cannot completely inhibit the disease process, but can easily lead to the activation of other compensation pathways.
BsAb can specifically block multiple signaling pathways to achieve better disease suppression effects.
The third is to use the antibody bivalent structure to mediate the formation of protein complexes and exert biological effects.
Emicizumab, a bispecific antibody targeting coagulation factors IXa and X, launched in 2017, is a humanized bispecific IgG4 antibody.
The mechanism of action is to bridge the binding factor IXa and factor X at the same time, thereby simulating the physiological function of FVⅢ.
Promote the production of thrombin.
As of October 2020, 3 dual-antibody drugs have been approved for marketing worldwide, with indications including tumors and hemophilia.
Tumor tumor tumor In 2018, 27 of the 28 newly initiated clinical trials of dual-antibody drugs were on the tumor direction.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
In 2019, there were more than 85 commercialized dual antibody pipelines in the clinical stage worldwide, and the indications were further concentrated on tumors, accounting for 86%.
As a new generation of antibody technology, the development of bispecific antibodies is still at an early stage.
At present, the global research and development of dual-antibody drugs is mainly concentrated in phase I and phase II clinical studies, and a small number of drugs are in phase III clinical studies.
The dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
Pharmaceutical companies Pharmaceutical pharmaceutical business enterprisesThe dual-antibody drugs that are in the late stage of clinical and marketing application in my country are all imported products.
Compared with multinational companies, the development of dual-antibody drugs by domestic companies is still in the early stage, and nearly 60% of the products are in the pre-clinical research stage.
Corning Jerry, Kangfang Sheng was able Kin Long, Friends of the Friends of Chi biological, bio-shore step biological pharmaceutical enterprises have the layout of dual anti-drugs.
Some large domestic pharmaceutical companies have also begun to deploy in this field.
In 2015, Innovent and Eli Lilly reached a global development cooperation agreement for three tumor immunotherapy bispecific antibody drugs; Livzon Pharmaceuticals became a shareholder of AbCyte Therapeutics in 2016 and acquired AbCyt.
e’s monoclonal antibody and bi-antibody technology platform in China; Simcere Pharmaceutical obtained the exclusive authorization of Merus in 2018 to use Merus’ proprietary BiclonicsR in China
Technology platform development and commercialization of three bispecific antibodies.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
On the whole, the competitive landscape of domestic bispecific antibodies is relatively good.
Dual antibody drugs have shown better efficacy than monoclonal antibody combination therapy, CAR-T and small molecule drugs, and effective responses have even appeared in patients whose existing therapies have failed or developed drug resistance.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
With the advancement of technology and the advancement of clinical trials, double-antibody drugs are expected to fill the defects of existing therapies in some indications and become important clinical treatment options in the future.
